Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft

Primary Objective Estimate event free survival (EFS) (relapse, progression, or death) rate one year after transplant. Secondary Objectives: 1. Estimate the cumulative incidences of severe acute grade III or higher GVHD, chronic GVHD (overall and by extent) 2. Estimate the cumulative incidence of systemic steroid initiation, 3. Summarize the graft failure frequency, 4. Summarize the kinetics of neutrophil and platelet recovery, and kinetics of donor chimerism in unsorted and CD3+ sorted peripheral blood. 5. Summarize major toxicities and complications associated with the transplantation procedure selected toxicities. Exploratory Objectives: Explore the association between the amount of donor T cell chimerism at \~ Day 28 and patient/graft characteristics (e.g., prior therapies, graft cell dose) and transplantation outcomes (sustained engraftment, relapse or progression, GVHD).